Since it has been reported that the expression level of Bcl‐xL is higher in lymph nodes than in peripheral blood in CLL patients [48], it will be of interest to determine how this impacts drug sensitivity to MEK/Bcl‐2 inhibition in vivo. Here, MAP2K7 is linked to B-cell chronic lymphocytic leukemia.